Servier Ventures
Corporate VC arm of French pharma Servier; participated in Cytospire's £61m Series A.
Last refreshed: 13 May 2026 · Appears in 1 active topic
Timeline for Servier Ventures
Cytospire's £61m oncology Series A oversubscribed
UK Startups and Innovation- What is Servier Ventures?
- Servier Ventures is the corporate venture Arm of Servier, a private French pharma company founded in 1954, investing strategically in oncology, immunology, and neurology.Source: Servier
- Who backed Cytospire's gamma delta T cell engager programme?
- Cytospire's £61m Series A was backed by Abingworth, Servier Ventures, Sound Bioventures, LifeArc Ventures, and Medical Incubator Japan.Source: Lowdown uk-startups-and-innovation U#4
- Is Servier a public or private company?
- Servier is private and employee-owned, unusual for a major pharmaceutical company. It was founded in France in 1954 and remains unlisted.Source: Servier
Background
Servier Ventures participated in Cytospire's £61m Series A in May 2026 alongside Abingworth, Sound Bioventures, LifeArc Ventures, and Medical Incubator Japan. Cytospire is advancing CYT X300, a first-in-class pan-gamma delta T cell engager targeting solid tumours.
Servier Ventures is the corporate venture capital Arm of Servier, a French pharmaceutical company headquartered in Paris and founded in 1954. Servier is unusual in pharma in remaining a private, employee-owned company rather than publicly listed. Servier Ventures focuses on strategic investments in oncology, immunology, and neurology — areas aligned with Servier's research pipeline — with a particular interest in novel immune engagement modalities. As a corporate investor, it provides both financial capital and potential partnership value for Servier's own R&D programmes.